Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met

Overview

Journal Phytother Res

Publisher Wiley

Date 2016 Jan 9

PMID 26744260

Citations 17

Authors

Hassan Y Ebrahim

Heba E Elsayed

Mohamed M Mohyeldin

Mohamed R Akl

Joydeep Bhattacharjee

Susan Egbert

Khalid A El Sayed

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a major health problem affecting the female population worldwide. The triple-negative breast cancers (TNBCs) are characterized by malignant phenotypes, worse patient outcomes, poorest prognosis, and highest mortality rates. The proto-oncogenic receptor tyrosine kinase c-Met is usually dysregulated in TNBCs, contributing to their oncogenesis, tumor progression, and aggressive cellular invasiveness that is strongly linked to tumor metastasis. Therefore, c-Met is proposed as a promising candidate target for the control of TNBCs. Lichens-derived metabolites are characterized by their structural diversity, complexity, and novelty. The chemical space of lichen-derived metabolites has been extensively investigated, albeit their biological space is still not fully explored. The anticancer-guided fractionation of Usnea strigosa (Ach.) lichen extract led to the identification of the depsidone-derived norstictic acid as a novel bioactive hit against breast cancer cell lines. Norstictic acid significantly suppressed the TNBC MDA-MB-231 cell proliferation, migration, and invasion, with minimal toxicity to non-tumorigenic MCF-10A mammary epithelial cells. Molecular modeling, Z'-LYTE biochemical kinase assay and Western blot analysis identified c-Met as a potential macromolecular target. Norstictic acid treatment significantly suppressed MDA-MB-231/GFP tumor growth of a breast cancer xenograft model in athymic nude mice. Lichen-derived natural products are promising resources to discover novel c-Met inhibitors useful to control TNBCs.

Citing Articles

Two Novel Compounds Isolated from the Marine Fungal Symbiont of Induce Apoptosis and Cell Cycle Arrest in Breast Cancer Cells: In vitro Study.

Bashari M, Agung M, Ariyanto E, Al Muqarrabun L, Salsabila S, Chahyadi A J Exp Pharmacol. 2025; 17:37-50.

PMID: 39867869 PMC: 11766706. DOI: 10.2147/JEP.S494777.

Cytotoxicity of norstictic acid derivatives, a depsidone from Nyl.

Bogo D, Alcantara I, Alcantara G, Micheletti A, Honda N, de Fatima C Matos M Turk J Chem. 2024; 48(5):748-755.

PMID: 39512745 PMC: 11539907. DOI: 10.55730/1300-0527.3694.

Unveiling the therapeutic potential of extract and its depsides/depsidones in combatting A42 peptides aggregation and neurotoxicity in Alzheimer's disease.

Yang M, Yan C, Ospondpant D, Wang L, Lin S, Tang W Front Pharmacol. 2024; 15:1426569.

PMID: 39193345 PMC: 11347406. DOI: 10.3389/fphar.2024.1426569.

Discovery of Fungus-Derived Nornidulin as a Novel TMEM16A Inhibitor: A Potential Therapy to Inhibit Mucus Secretion in Asthma.

Pongkorpsakol P, Yimnual C, Satianrapapong W, Worakajit N, Kaewin S, Saetang P J Exp Pharmacol. 2023; 15:449-466.

PMID: 38026233 PMC: 10657771. DOI: 10.2147/JEP.S427594.

Bioactive Lichen Secondary Metabolites and Their Presence in Species from Chile.

Poulsen-Silva E, Gordillo-Fuenzalida F, Atala C, Moreno A, Otero M Metabolites. 2023; 13(7).

PMID: 37512512 PMC: 10383681. DOI: 10.3390/metabo13070805.

References

Duffy M, McGowan P, Crown J . Targeted therapy for triple-negative breast cancer: where are we?. Int J Cancer. 2012; 131(11):2471-7. DOI: 10.1002/ijc.27632. View

White P, Oliveira R, Oliveira A, Serafini M, Araujo A, Gelain D . Antioxidant activity and mechanisms of action of natural compounds isolated from lichens: a systematic review. Molecules. 2014; 19(9):14496-527. PMC: 6271897. DOI: 10.3390/molecules190914496. View

Reis-Filho J, Pusztai L . Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378(9805):1812-23. DOI: 10.1016/S0140-6736(11)61539-0. View

Elsayed H, Akl M, Ebrahim H, Sallam A, Haggag E, Kamal A . Discovery, optimization, and pharmacophore modeling of oleanolic acid and analogues as breast cancer cell migration and invasion inhibitors through targeting Brk/Paxillin/Rac1 axis. Chem Biol Drug Des. 2014; 85(2):231-43. DOI: 10.1111/cbdd.12380. View

Steeg P . Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12(8):895-904. DOI: 10.1038/nm1469. View

Comoglio P, Giordano S, Trusolino L . Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008; 7(6):504-16. DOI: 10.1038/nrd2530. View

Akl M, Ayoub N, Mohyeldin M, Busnena B, Foudah A, Liu Y . Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS One. 2014; 9(5):e97622. PMC: 4029740. DOI: 10.1371/journal.pone.0097622. View

Molnar K, Farkas E . Current results on biological activities of lichen secondary metabolites: a review. Z Naturforsch C J Biosci. 2010; 65(3-4):157-73. DOI: 10.1515/znc-2010-3-401. View

Dorsch D, Schadt O, Stieber F, Meyring M, Gradler U, Bladt F . Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. Bioorg Med Chem Lett. 2015; 25(7):1597-602. DOI: 10.1016/j.bmcl.2015.02.002. View

10.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

11.

Organ S, Tsao M . An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011; 3(1 Suppl):S7-S19. PMC: 3225017. DOI: 10.1177/1758834011422556. View

12.

Dussault I, Bellon S . c-Met inhibitors with different binding modes: two is better than one. Cell Cycle. 2008; 7(9):1157-60. DOI: 10.4161/cc.7.9.5827. View

13.

Akl M, Ayoub N, Ebrahim H, Mohyeldin M, Orabi K, Foudah A . Araguspongine C induces autophagic death in breast cancer cells through suppression of c-Met and HER2 receptor tyrosine kinase signaling. Mar Drugs. 2015; 13(1):288-311. PMC: 4306938. DOI: 10.3390/md13010288. View

14.

Galluzzi L, Aaronson S, Abrams J, Alnemri E, Andrews D, Baehrecke E . Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009; 16(8):1093-107. PMC: 2757140. DOI: 10.1038/cdd.2009.44. View

15.

Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S . Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene. 2002; 21(15):2309-19. DOI: 10.1038/sj.onc.1205297. View

16.

Trusolino L, Bertotti A, Comoglio P . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010; 11(12):834-48. DOI: 10.1038/nrm3012. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

18.

Nguyen D, Bos P, Massague J . Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9(4):274-84. DOI: 10.1038/nrc2622. View

19.

Cecchi F, Rabe D, Bottaro D . Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer. 2010; 46(7):1260-70. PMC: 3412517. DOI: 10.1016/j.ejca.2010.02.028. View

20.

Danilkovitch-Miagkova A, Zbar B . Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002; 109(7):863-7. PMC: 150937. DOI: 10.1172/JCI15418. View